Cadrenal Therapeutics, Inc. CVKD PHARMA
Company Overview
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.00.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -89.73% |
| 6 Months: | -85.00% |
| 3 Months: | -71.50% |
| 1 Month: | -38.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)25.51 · Oversold
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 91.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CVKD Cadrenal Therapeutics, Inc. PHARMA | 1.20 | -0.25 | $3.72M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -170.52K | -482.35K | -972.79K | -4.20M | -1.03M | -1.14M | -1.76M | -2.47M | -2.46M | -3.93M | -3.73M | -2.73M | -2.51M |
| Net Income | -176.65K | -502.14K | -1.03M | -5.17M | -1.00M | -1.04M | -1.66M | -2.39M | -2.41M | -3.85M | -3.67M | -2.69M | -2.50M |
| Diluted EPS | -0.02 | 0.07 | -0.13 | -0.48 | -0.09 | -1.01 | -1.56 | -2.24 | -2.18 | -2.09 | -1.87 | -1.31 | -1.04 |
| R&D Expense | - | - | 56.39K | 3.24M | 240.96K | 243.95K | 629.02K | 1.25M | 784.65K | 1.67M | 1.08M | 688.47K | 771.51K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -2.70M | -7.63M | -10.96M | -13.46M |
| Net Income | -6.71M | -8.36M | -10.65M | -13.24M |
| Diluted EPS | -0.85 | -9.29 | -8.73 | -6.64 |
| R&D Expense | 392.86K | 4.08M | 4.21M | 4.10M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 778.17K | 8.52M | 10.12M | 4.33M |
| Current Assets | 727.60K | 8.49M | 10.11M | 4.32M |
| Cash & Equivalents | 32.59K | 8.40M | 10.02M | 4.01M |
| Inventory | - | - | - | - |
| Receivables | - | 37.25K | 38.15K | 5.10K |
| Total Liabilities | 6.33M | 826.88K | 2.68M | 1.59M |
| Current Liabilities | 1.33M | 826.88K | 2.68M | 1.59M |
| Long Term Debt | 553.34K | - | - | - |
| Total Debt | 640.71K | 21.35K | 0 | - |
| Total Equity | -5.55M | 7.69M | 7.44M | 2.74M |
| Shares Outstanding | 775.64K | 868.18K | 1.78M | 2.34M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -1.20M | -3.53M | -7.36M | -12.60M |
| Investing Cash Flow | -2.28K | -3.25K | -6.54K | -5.10K |
| Financing Cash Flow | 1.24M | 11.90M | 8.98M | 6.60M |
| Capital Expenditure | -2.28K | -3.25K | -6.54K | -5.10K |
| Free Cash Flow | -1.21M | -3.53M | -7.36M | -12.61M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 121.0% | -108.6% | -143.2% | -483.3% |
| ROCE % | 485.6% | -99.2% | -147.3% | -491.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.41% | 50.14K | $53.65K |
| 2 | HRT Financial LP | 0.81% | 29.05K | $31.09K |
| 3 | Geode Capital Management, LLC | 0.53% | 19.02K | $20.36K |
| 4 | Vanguard Fiduciary Trust Co | 0.23% | 8.31K | $8.89K |
| 5 | Corecap Advisors, LLC | 0.04% | 1.28K | $1.37K |
| 6 | Tower Research Capital LLC (TRC) | 0.04% | 1.28K | $1.37K |
| 7 | Grove Bank & Trust | 0.03% | 1.00K | $1.07K |
| 8 | UBS Group AG | 0.03% | 1.11K | $1.19K |
| 9 | Clearstead Advisors, LLC | 0.02% | 650 | $695 |
| 10 | Morgan Stanley | 0.02% | 706 | $755 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CVKD
Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote, News & History - Benzinga
<a href="https://news.google.com/rss/articles/CBMiS0FVX3lxTFBZTzQ1TnVKZmhTYXpBNGs5Vms4N09xc29ubVBIWGVrMnZ0VGowM0ZYclBaREpsSjdwTV93cWxRamVQNWh6S2xILXdoVQ?oc=5" target="_blank">Cadrenal Therapeutics Inc (CVKD) Stock Price, Quote, News & Histo…
$CVKD stock is up 12% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNdnlvN1ZabmVYSGVsR3dsaEJ1c2Q3a3dIVGR4Q1RrTWhIZTYtdENSTW9CUVJTbk9TVk0tRHlxcG9NQ2oxOVVkVU1kWTlHaVdfUTAyT2l4RTNqNUtjV1kwV1pPMW56VFd5N2ZaTVJ3OXYxVGhZckk1T0JJSDF6TDJnS1RJLUxmZDhRYU0zX3…
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGY4dmJrWXBHUEVvcmFKV1h2eFljbkFMeEV4YW5wN0Y4Z241c2tuMDA3MDFvYVRiektPMC1HRjhiSERPbjN3X2tibzhTQXZDbUNRMEJHLUNEZm14OVl1ZVd3S2lMVnBCclNoR0lJR25ydWE2ekNZQ1VtZlpNVFk5YmxYQnBXQXBHX19US1…
CVKD Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1tdzZ2MXVYMGZ5T21lZWRFYWNJSUtkRDZWU1FxYkY4ZUlHR29XeVI0TVFEME9WbHpoT0tsSDFSaVFsUllNWV85N1hHdmlDTURVanQ5ZElVaUU1YW9QVHVfU05BZDJLLXZETmNkd1c3SkZtNUJMSUhmSlB3?oc=5" target="_blank">CVK…
FDA agrees to a placebo trial for a drug aimed at a blood reaction affecting 50,000 yearly - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNT0IzaTRCM19hbTROdU9NeFEtWEdSYWtYUGdJSy12TUFBNXRYa0lnZ29NRENPZTFLVnFKQ2Q5MU85Rk5tM3BJci1GLXlEeWsyRFdxY2k4WXliaVNnOUpKNUdNWkQ4S1BKN0l5cGloMWR0WUdjWlotdEZCZmdXR05MdEpLeTRPMlh2dzU2aH…
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOeVFjUklHOVlZSE9YdkdHSHpINUJvdldRaC15Yld0LVlkU1hYcHpKY2dHejRkVC1FdDlIcjlnaGpjVlAzNzJvbXBOdm54TlM1cENMYXJaZnRHRUtkRUhWdDN3R0FQRUpjN1Y5ZmJkQnFScXlUSmY3YUlCMWh6cHBFV3VZX3g0Y1FReXhSaT…
CVKD — Frequently Asked Questions
What is the current share price of Cadrenal Therapeutics, Inc. (CVKD)?
As of 2026-09-19 21:16 PDT, Cadrenal Therapeutics, Inc. (CVKD) trades at $1.20 on NasdaqCM. Its 52-week range is $1.20 to $14.20.
What is the market capitalisation of CVKD?
Cadrenal Therapeutics, Inc. (CVKD) has a market capitalisation of $3.72M on NasdaqCM.
What is the P/E ratio of CVKD?
CVKD trades at a trailing price-to-earnings (P/E) ratio of -0.25. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.90.
Is CVKD a good stock to buy?
This page provides a data-driven analysis of Cadrenal Therapeutics, Inc. (CVKD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.